Hough C, Fukamauchi F, Chuang D M
Section on Molecular Neurobiology, National Institute of Mental Health, Bethesda, Maryland 20892.
J Neurochem. 1994 Feb;62(2):421-30. doi: 10.1046/j.1471-4159.1994.62020421.x.
Microtubule disrupter, colchicine, and microtubule stabilizer, taxol, were used to determine whether microtubules play a role in beta-adrenergic receptor mRNA homeostasis and agonist-induced down-regulation in C6 glioma cells. Colchicine treatment had significant, differential, time-dependent effects on constitutive beta 1- and beta 2-adrenergic receptor mRNA levels. These effects stemmed from the action of colchicine on microtubules, because beta-lumicolchicine, an inactive isomer, had no effect, and nocodazole, a structurally unrelated microtubule disrupter, had similar effects. Colchicine treatment had little effect on the total number of beta-adrenergic receptor binding sites as measured by (-)-[125I]iodopindolol binding, but did alter the relative proportion of beta 1- and beta 2-adrenergic receptor subtypes. Colchicine also had no effect on basal cyclic AMP levels. In contrast to colchicine, taxol treatment had little long-term effect on either beta 1- or beta 2-adrenergic receptor mRNA levels. Taxol antagonized the effects of colchicine on total binding and mRNA levels. Taxol treatment increased basal cyclic AMP levels fourfold and potentiated (-)-isoproterenol-induced cyclic AMP production. Colchicine pretreatment completely inhibited (-)-isoproterenol-induced down-regulation of beta 1-adrenergic receptor mRNA, but not that of beta 2-adrenergic receptor mRNA. Taxol pretreatment had little effect on isoproterenol-induced beta-adrenergic receptor mRNA down-regulation. Colchicine pretreatment also attenuated isoproterenol-induced receptor down-regulation and inhibited agonist-stimulated cyclic AMP production. These effects of colchicine were antagonized by taxol. Whereas the effects of taxol and colchicine on isoproterenol-induced down-regulation of beta-adrenergic receptor mRNA are consistent with their effects on cyclic AMP production, those of colchicine in the absence of stimulation must involve other mechanisms. The data demonstrate that the state of microtubule assembly can affect cyclic AMP levels, beta 1- and beta 2-adrenergic receptor mRNA, and binding site levels in C6 glioma cells.
使用微管破坏剂秋水仙碱和微管稳定剂紫杉醇,来确定微管是否在C6胶质瘤细胞中β-肾上腺素能受体mRNA的稳态及激动剂诱导的下调过程中发挥作用。秋水仙碱处理对组成型β1-和β2-肾上腺素能受体mRNA水平具有显著、不同且时间依赖性的影响。这些影响源于秋水仙碱对微管的作用,因为无活性异构体β-光秋水仙碱没有影响,而结构不相关的微管破坏剂诺考达唑具有类似作用。通过(-)-[125I]碘吲哚洛尔结合测定,秋水仙碱处理对β-肾上腺素能受体结合位点总数影响不大,但确实改变了β1-和β2-肾上腺素能受体亚型的相对比例。秋水仙碱对基础环磷酸腺苷水平也没有影响。与秋水仙碱相反,紫杉醇处理对β1-或β2-肾上腺素能受体mRNA水平几乎没有长期影响。紫杉醇拮抗秋水仙碱对总结合和mRNA水平的影响。紫杉醇处理使基础环磷酸腺苷水平增加四倍,并增强(-)-异丙肾上腺素诱导的环磷酸腺苷生成。秋水仙碱预处理完全抑制(-)-异丙肾上腺素诱导的β1-肾上腺素能受体mRNA下调,但不抑制β2-肾上腺素能受体mRNA下调。紫杉醇预处理对异丙肾上腺素诱导的β-肾上腺素能受体mRNA下调影响不大。秋水仙碱预处理还减弱了异丙肾上腺素诱导的受体下调,并抑制激动剂刺激的环磷酸腺苷生成。秋水仙碱的这些作用被紫杉醇拮抗。虽然紫杉醇和秋水仙碱对异丙肾上腺素诱导的β-肾上腺素能受体mRNA下调的作用与其对环磷酸腺苷生成的作用一致,但秋水仙碱在无刺激情况下的作用肯定涉及其他机制。数据表明,微管组装状态可影响C6胶质瘤细胞中的环磷酸腺苷水平、β1-和β2-肾上腺素能受体mRNA以及结合位点水平。